Introduction
============

Breast cancer is one of the most common malignant tumors in females, while metastases to the breast from non-breast solid tumors are rare, accounting for only 0.3--2% of all malignant mammary tumor types ([@b1-ol-0-0-7741],[@b2-ol-0-0-7741]). To date, \<500 cases of cancer with secondary involvement of the breast from any non-breast solid tumors have been reported ([@b2-ol-0-0-7741],[@b3-ol-0-0-7741]). On the basis of the limited number of studies available in the literature, excluding contralateral breast cancer and lymphoma, the most frequent source of primary malignancies with metastases to the breast in Western countries are melanoma and lung cancer ([@b3-ol-0-0-7741]--[@b5-ol-0-0-7741]). Other reported primary sources include the ovary, gastrointestinal tract, thyroid, kidney and sarcomas of different origins ([@b6-ol-0-0-7741]--[@b8-ol-0-0-7741]). In general, symptoms of metastases to the breast are similar to those of primary breast cancer, including the presence of a palpable, freely-movable mass within the breast. Pain, tenderness and inflammation are also observed occasionally. Considering the rarity of extramammary lesions, it is challenging to distinguish these lesions from primary breast cancer, even in patients with a history of a primary non-breast solid tumor ([@b1-ol-0-0-7741]--[@b4-ol-0-0-7741]). However, the poor prognosis of patients with secondary breast metastases and the contrast in appropriate treatments compared with those for patients with primary breast cancer, in addition to the fact that systemic treatment or palliative care is more appropriate than extensive surgery in the majority of patients with secondary breast metastases, emphasizes the importance of accurate diagnosis ([@b1-ol-0-0-7741]--[@b6-ol-0-0-7741]). In the present study, a single-institution retrospective review of 22 patients with pathologically confirmed extramammary metastases to the breast, treated at the Sun Yat-sen University Cancer Center (Guangzhou, China), was conducted. The clinical, radiological, pathological and prognostic data of these patients were summarized in order to identify their clinical characteristics, describe their histological and immunohistochemical features and to assess their clinical outcomes. The results may serve as a future reference for the Southern Chinese population.

Patients and methods
====================

### Patients

Retrospective data were obtained from electronic medical records and pathology databases at the Sun Yat-sen University Cancer Center (Guangzhou, China) between January 2000 and December 2015 for patients with biopsy-diagnosed metastasis to the breast from an on-breast primary solid tumor site. Tissues were also obtained within the same time frame. Metastases from contralateral primary breast cancer or hematological malignancies were excluded. All histological slices were reviewed by two pathologists.

Medical records from 22 patients (2 males, 20 females; mean age, 40.5 years; range, 10--62 years) were included in the present study. Data collected from the records included the following: Age, sex, initial symptoms, history of primary tumor, interval from the diagnosis of the primary tumor to breast metastases, other metastases status, tumor status at presentation of breast metastasis, ultrasonographic and mammographic findings, biopsy or post-surgery pathology results, clinical treatments and follow-up. The breast imaging-reporting and data system (BI-RADS) I to VI categorization ([@b9-ol-0-0-7741]), developed by the American College of Radiology, was applied in present study.

### Statistical analysis

Descriptive statistics were applied to assess frequency distributions. Overall survival interval probabilities were calculated using the Kaplan-Meier method and differences in survival were assessed by the log-rank test using SPSS 19.0 (IBM Corp., Armonk, NY, USA). P\<0.05 was determined to indicate statistically significant difference.

Results
=======

### Demographic characteristics of patients with metastases to the breast

Demographic characteristics of 22 patients with metastases to the breast are summarized in [Table I](#tI-ol-0-0-7741){ref-type="table"}. Patients were predominately female (2 males, 20 females). The mean and median onset of age for breast metastasis was 40.5 and 43 years, respectively (range, 10--62 years). A total of 19 (86.4%) patients had a documented history of a primary tumor with a mean interval of 6.5 months (range, 6--56 months) between diagnosis of the primary tumor to detection of breast metastasis. In the other 3 patients (13.6%), the primary tumor and breast metastasis were diagnosed simultaneously with intact primary disease. A total of 7 patients (31.8%) presented with other metastases and 11 patients (50.0%) exhibited no evidence of a primary tumor or other metastasis when breast metastasis was located. Pulmonary metastasis had been confirmed and treated in one patient with melanoma when breast metastasis presented. Overall, the breast was the only metastatic site in 6 (27.3%) patients.

### Clinical characteristics of patients with metastases to the breast

Breast metastasis were initially detected by self-checking in 14 patients (63.6%; [Table II](#tII-ol-0-0-7741){ref-type="table"}). The mean tumor size was 2.9 cm (range, 0.8--12.0 cm). A unilateral (45.5% left, 36.4% right), upper outer quadrant (15/22, 68.2%) lesion of the breast was most frequently diagnosed; bilateral lesions were present in 4 patients (18.2%). Clinically, 14 patients (63.6%) presented with a palpable painless solitary mass, 8 (36.4%) had multiple nodules, 1 (4.5%) exhibited skin and nipple changes and 2 (9.1%) reported tenderness. A total of 10 (45.5%) patients had palpable enlarged axillary lymph nodes, of which 4 patients (18.2%) presented with enlarged supraclavicular lymph nodes simultaneously.

### Ultrasonic and mammographic findings of breast metastases

Among the 22 patients who underwent radiologic imaging ([Table III](#tIII-ol-0-0-7741){ref-type="table"}), 14 patients underwent breast ultrasonography and 5 patients underwent a mammography. In mammography, the most common finding was a single mass with either circumscribed (3/5, 60%) or speculated (2/5, 40%) margins. Only 1 (20%) patient who underwent a mammography presented with a lesion classified as a BI-RADS category I which refers to a negative examination by mammography, and the rest (4/5, 80%) presented lesions categorized as BI-RADS category IVb or greater, which refers to a high probability of malignancy. In ultrasonography, breast lesions were primarily hypoechoic and margins may be either circumscribed (8/14, 57.1%) or speculated (6/14, 42.9%). The vascularity (8/14, 57.1%) of the lesions and BI-RADS category V (7/14, 50%) were most commonly identified. Calcifications were observed in only 2 cases in ultrasonography (14.3%) and mammography (40%) each.

### Histological features in different types of carcinoma and non-carcinoma in patients with breast metastases

Histological features of different tumor types and primary tumor sites are presented in [Tables IV](#tIV-ol-0-0-7741){ref-type="table"} and [V](#tV-ol-0-0-7741){ref-type="table"}. Carcinoma was the most common tumor type for non-mammary metastases (16/22, 72.7%; [Table IV](#tIV-ol-0-0-7741){ref-type="table"}), followed by melanoma (3/22, 13.6%; [Table V](#tV-ol-0-0-7741){ref-type="table"}) and sarcoma (2/22, 9.1%; [Table V](#tV-ol-0-0-7741){ref-type="table"}). The remaining patient presented with a rare Wilms\' tumor metastasis to the breast ([Table V](#tV-ol-0-0-7741){ref-type="table"}). The most frequent primary tumor site for carcinoma was the lungs (5/22, 22.7%, [Fig. 1](#f1-ol-0-0-7741){ref-type="fig"}), followed by the nasopharynx (4/22, 18.2%; [Fig. 2](#f2-ol-0-0-7741){ref-type="fig"}) and ovary (3/22, 13.6%; [Fig. 3](#f3-ol-0-0-7741){ref-type="fig"}). Other primary sites included the gastrointestinal tract (2/22, 9.1%) and thyroid (1/22, 4.5%). Of the three melanoma cases, two initially occurred at cutaneous sites and one was ocular ([Fig. 4](#f4-ol-0-0-7741){ref-type="fig"} and [Table V](#tV-ol-0-0-7741){ref-type="table"}). The two cases of sarcoma were rhabdomyosarcoma ([Fig. 5](#f5-ol-0-0-7741){ref-type="fig"}), with the primary sites being the palm and nasal cavity ([Table V](#tV-ol-0-0-7741){ref-type="table"}).

Immunohistochemistry (IHC) was performed in 15 patients (68.2%) in total. Of these, lung cancer was the most frequent tumor identified (5/15, 33.3%), followed by tumors of asopharynx (3/15, 20.0%), ovary (2/15, 13.3%), melanoma (2/15, 13.3%), rhabdomyosarcoma (1/15, 6.7%; data not shown), Wilms\' tumor (1/15, 6.7%) and thyroid (1/15, 6.7%; data not shown). The most frequently used markers included the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), mammaglobin, gross cystic disease fluid protein-15 (GCDFP-15), cytokeratin, p63, transcription termination factor-1 (TTF-1), S-100 by IHC and Epstein-Barr virus-encoded RNA (EBER) by *in situ* hybridization, which together with the primary tumor history, were conducive for accurate diagnosis.

Surgical resection of the breast was performed in 17 patients (77.3%): 7 patients (31.8%) had modified radical mastectomy and 10 patients (45.5%) had breast-conserving surgery (data not shown). Follow-up data were available in 20 cases. The median survival duration from diagnosis of metastases to the breast was 35 months (range, 2--106 months). A total of 10 patients (45.5%) succumbed from the disease. Univariate analysis was applied to evaluate different interventions on overall survival ([Figs. 6](#f6-ol-0-0-7741){ref-type="fig"}--[8](#f8-ol-0-0-7741){ref-type="fig"}). Patients who underwent surgery had a median survival duration of 74 months, while patients who did not undergo surgery survived for a median duration of 12 months (P=0.023; [Fig. 7](#f7-ol-0-0-7741){ref-type="fig"}). However, the difference in survival observed among patients who underwent modified radical mastectomy, breast-conserving surgery and non-surgical intervention was not significant (P=0.301; [Fig. 8](#f8-ol-0-0-7741){ref-type="fig"}).

Discussion
==========

Metastasis to the breast may occur in various types of non-breast solid tumor; however, cases of this are extremely rare ([@b1-ol-0-0-7741]--[@b5-ol-0-0-7741],[@b10-ol-0-0-7741]). Additionally, the therapeutic strategies used to treat these cases are extremely different from those used to treat primary breast cancer, making the history of the primary tumor particularly important for the achievement of an accurate diagnosis ([@b10-ol-0-0-7741]). Williams *et al* ([@b3-ol-0-0-7741]) and Lee *et al* ([@b4-ol-0-0-7741]) demonstrated that a documented history of a primary tumor was observed in 72--88% of patients with breast metastases, and that these metastases more frequently occurred in females, which is consistent with the results of the present study. The results of the present study also demonstrated that the breast lesion was the initial or only metastasis in half of the patients, which is inconsistent with previous studies ([@b4-ol-0-0-7741],[@b10-ol-0-0-7741]--[@b13-ol-0-0-7741]), which demonstrated that these metastases are most likely to originate from carcinoma of genital organs (3/4, 75.0%) and non-carcinoma (5/6, 83.3%). These inconsistencies may be due to the variance in pathological cancer types and the young onset age of 40.5 years in the patients used in the current study, which is an age group that remains at high risk of breast cancer ([@b14-ol-0-0-7741]). Other previous studies have indicated that there is a higher incidence of metastasis to the breast from non-breast solid tumors that occur in adolescence ([@b15-ol-0-0-7741]), as well as during lactation and pregnancy ([@b16-ol-0-0-7741]), owing to the change in hormonal status during these periods. Longer median time (2 years) intervals from the point of diagnosis of the primary tumor to breast metastasis compared with those in the current study have also been reported ([@b17-ol-0-0-7741]).

A single palpable painless mass located in the upper outer quadrant of the breast was the most common initial clinical feature reported in the current study. Akcay *et al* ([@b2-ol-0-0-7741]) demonstrated that the breast metastases were frequently multiple and bilateral, which was observed in 36.4% (8/22) and 18.2% (4/22) of patients in the current study, respectively. Laterality was not present at either side of the breast, which was inconsistent with earlier studies ([@b3-ol-0-0-7741],[@b4-ol-0-0-7741],[@b17-ol-0-0-7741]). Lee *et al* ([@b4-ol-0-0-7741]) suggested that a preponderant lymphatic pathway to the breast from other organs may contribute to laterality; however, further investigations are required. Considering the rarity of breast metastases, a new primary breast cancer may be considered 'preferable' for the breast lesion even in patients with a history of definite primary extramammary malignancy ([@b3-ol-0-0-7741],[@b4-ol-0-0-7741],[@b17-ol-0-0-7741]). Radiological imaging also aids the establishment of a more accurate diagnosis ([@b18-ol-0-0-7741]).

Previous ultrasonic and mammographic images studies demonstrated that it is occasionally difficult to distinguish breast metastases, which appeared as a hypoechoic or high-density well-circumscribed and freely movable mass, from primary breast cancer which displays a hypoechoic mass with speculated margin or a diffuse lesions with or without calcifications ([@b5-ol-0-0-7741],[@b18-ol-0-0-7741],[@b19-ol-0-0-7741]). However, despite the absence of diffuse lesions, 42.9% of the patients in the current study presented with a mass with a speculated margin. Calcifications are rarely observed in breast metastases ([@b20-ol-0-0-7741],[@b21-ol-0-0-7741]), with the exception of metastatic ovarian papillary carcinoma with psammoma bodies ([@b22-ol-0-0-7741],[@b23-ol-0-0-7741]), which is consistent with the results of the current study. Two cases of breast metastasis from lung adenocarcinoma with calcifications was also presented in the current study. Breast lesions were classified as BI-RADS IVA or greater in the majority of cases in the present study; the others were categorized as BI-RADS I--III, suggesting that a metastatic mass from a solitary cyst should be distinguished from a metastatic mass from a fibroadenoma, particularly in postmenopausal women or women with a known history of cancer. Posterior echo enhancement and vascularity demonstrated by Color Doppler have previously been used to accurately identify a lesion as either a metastatic melanoma or sarcoma ([@b5-ol-0-0-7741],[@b24-ol-0-0-7741]) and the results of the present study revealed that posterior echoic enhancement and vascularity were observed in all three cases of breast metastases from melanoma. Asian women have smaller breasts with higher gland density and lower lipid content ([@b25-ol-0-0-7741]) than women from Western countries. The lack of calcification may therefore lead to misdiagnosis of breast lesions by mammography ([@b5-ol-0-0-7741],[@b22-ol-0-0-7741]). Further research comparing the accuracy of ultrasonic screening and mammography for diagnosis of breast metastases in Asian females is required. Computerized tomography and magnetic resonance imaging have also been used for diagnosis of breast metastases ([@b26-ol-0-0-7741],[@b27-ol-0-0-7741]); however, 95% of the patients in the present study underwent a biopsy followed by radiological imaging, confirming the diagnosis of breast metastasis.

Consistent with previous reports ([@b3-ol-0-0-7741],[@b15-ol-0-0-7741],[@b17-ol-0-0-7741]), lung adenocarcinoma, ovarian serous papillary carcinoma and melanoma were the most common primary carcinomas that metastasized to the breast. DeLair *et al* ([@b17-ol-0-0-7741]) also reported that lung adenocarcinoma and melanoma were more common in males. Previous studies have reported the relatively high incidence of gastric carcinoma ([@b4-ol-0-0-7741]) and lymphoma ([@b28-ol-0-0-7741]). To the best of our knowledge, the present study is the first to report nasopharyngeal carcinoma (NPC) as accounting for a high proportion (4/22) of primary tumors, with half of these cases occurring in men. The inconsistency between the results of the present and previous studies may be due to referral (the Sun Yat-sen University Cancer Center is known for its excellence in nasopharyngeal carcinomas care), geographical and/or racial biases, as there is a higher disease prevalence of nasopharyngeal carcinoma in southern Chinese Han males ([@b29-ol-0-0-7741],[@b30-ol-0-0-7741]). Typical morphological features of NPC, including cells with vesicular nuclei and positive *in situ* hybridization staining for EBERs, as well as immunostaining of cytokeratin 5/6 and p63, aided the achievement of a diagnosis of NPC in the current study. However, given the limited numbers of cases reported thus far, further investigation is required.

Breast metastases and primary breast cancer have common histological findings, including periductal and perilobular distribution, absence of ductal carcinoma *in situ*, lack of stromal reaction, including desmoplastic response and elastosis and a large number of lymphovascular tumor emboli ([@b4-ol-0-0-7741],[@b15-ol-0-0-7741],[@b31-ol-0-0-7741]). The majority of metastatic lesions have histological appearances consistent with their primary sites and thus, pathologists often identify a metastasis to the breast by comparing histological patterns to a previous sample from the patient ([@b4-ol-0-0-7741]). This evaluation was performed with metastatic melanoma, sarcoma, neuroendocrine carcinoma and Wilms tumor in the present study. Immunohistochemical staining for tumor-specific markers, including ER, PR, HER-2, mammaglobin, GCDFP-15 and GATA binding protein 3 (GATA3) for breast cancer; TTF-1 and Napsin A for lung adenocarcinoma; Wilms tumor protein, paired box protein PAX-8 (PAX-8) and CA-125 for ovarian carcinoma; CK20 and homeobox protein CDX-2 for gastrointestinal tract adenocarcinoma; CgA, NSE and Synapsin for neuroendocrine carcinoma; CK19 and thyroid peroxidase for thyroid carcinoma; S-100 and HMB-45 for melanoma; and myogenin for rhabdomyosarcoma aid diagnosis. However, several overlaps exist, including ER, PR and GCDFP-15 in histological appearance and immunophenotyping, particularly between ovarian carcinoma and primary breast cancer, often leading to difficulties in differential diagnosis ([@b32-ol-0-0-7741]). Prior studies have reported that GCDFP-15 was rarely observed in ovarian carcinoma ([@b33-ol-0-0-7741],[@b34-ol-0-0-7741]), whereas \~30% of primary breast cancer also did not exhibit GCDFP-15 expression ([@b34-ol-0-0-7741]). Other studies have reported that up to 95% of serous papillary carcinomas exhibit nuclear expression of WT-1and membrane expression of CA125, which is only present in \<10% of different types of breast cancer ([@b35-ol-0-0-7741]--[@b37-ol-0-0-7741]). A more recent study also suggested the value of GATA-3 and PAX-8 as biomarkers for breast cancer ([@b38-ol-0-0-7741],[@b39-ol-0-0-7741]). Consistent with a previous study ([@b3-ol-0-0-7741]), the results of the current study indicate that no single marker is absolutely specific and its expression is always variable between primary and metastatic lesions, particularly in tissue biopsies. Thus, a panel of IHC markers with the same pathology as that of the primary tumor, clinical history and imaging findings are required in combination for accurate diagnosis.

The prognosis of metastases to the breast remains poor ([@b1-ol-0-0-7741]--[@b4-ol-0-0-7741],[@b10-ol-0-0-7741],[@b17-ol-0-0-7741]). The median survival duration reported by Williams *et al* ([@b3-ol-0-0-7741]) (169 cases), DeLair *et al* ([@b17-ol-0-0-7741]) (85 cases) and Lee *et al* ([@b4-ol-0-0-7741]) (30 cases) was 10, 15 and 13.9 months, respectively, which is consistent with the results of the current study, in which the shortest survival duration following diagnosis was \>2 months. Over 70% of patients had widely metastatic disease in combination with the breast lesion, which is likely to be the main contributor to the poor survival observed in the present study. Individualized systemic therapeutic strategies for primary tumors should be recommended as the primary therapy in a majority of cases ([@b1-ol-0-0-7741]--[@b4-ol-0-0-7741],[@b10-ol-0-0-7741],[@b17-ol-0-0-7741]); however, the benefit of surgical resection of the breast remains controversial. Consistent with the findings of Williams *et al* ([@b3-ol-0-0-7741]), the results of the current study indicated improved overall survival in patients who underwent surgery compared with those who did not. However, there are limitations to the current study: The sample size was extremely small and there was selection bias, as surgery is not well tolerated in patients with advanced disease or poor health condition, as described previously ([@b3-ol-0-0-7741]). Previously, Rossfeld and Carson ([@b40-ol-0-0-7741]) proposed the benefit of metastasectomy and suggested the re-evaluation of the approach of 'sparing patients unnecessary surgery'. Understanding the patients\' therapeutic goals should be the determinant factor in treating metastatic lesions. Further multi-center clinical investigations are therefore required to address the characteristics of breast metastases that originate from non-breast solid tumor, as well as the effect of surgery on patient prognosis.

In summary, breast metastases are rare and primarily indicate a poor prognosis. Additionally, it may be easily misdiagnosed as a primary breast cancer. Clinical manifestations, radiologic findings and histopathological/immunohistochemical features should all be considered in differentiating a secondary mass from a primary breast cancer, even in patients without a history of primary malignant tumors. Early and accurate diagnosis is conducive to individualized treatment and improved prognosis improvement. In addition, surgical resection of breast metastases may result in a survival benefit, which remains yet to be further studied.

![Metastasis from lung adenocarcinoma to the breast. (A) A large quantity of lymphovascular tumor cell embolus with necrosis, which should be distinguished from ductal carcinoma *in situ*. Immunohistochemical analysis indicated the expression of (B) CD34 in vessels and (C) thyroid transcription factor-1 in tumor cells. Scale bar, 100 µm; magnification, ×10.](ol-15-03-3685-g00){#f1-ol-0-0-7741}

![Metastasis from non-keratinizing undifferentiated carcinoma of the nasopharynx to the breast. (A) Well-circumscribed lesion surrounded by a fibrous pseudocapsule in H&E staining. (B) Typical vesicular nucleus tumor cells with distinct nucleolus without keratinization in H&E staining at magnification, ×20. (C) *In situ* hybridization (ISH) for detection of Epstein-Barr virus-encoded RNA indicated that the tissues were EBV positive. Scale bar, 100 µm; magnification, ×10.](ol-15-03-3685-g01){#f2-ol-0-0-7741}

![Metastasis from serous papillary carcinoma of the ovary to the breast. (A) Micropapillary with calcification and (B) typical papillary architecture in H&E staining, which should be distinguished from invasive micropapillary carcinoma of the breast. Immunohistochemical staining indicated expression of (C) Wilms\' tumor 1 and (D) paired box protein PAX-8 in tumor cell nuclei. Scale bar, 100 µm; magnification, ×10.](ol-15-03-3685-g02){#f3-ol-0-0-7741}

![Metastasis from melanoma to the breast. (A) Typical spindle cells and pigment with necrosis in H&E staining. (B) Atypical small round blue cells with necrosis and myxoid stroma, no pigment is observed in H&E staining. (C) Immunohistochemical staining indicated S-100 expression. Scale bar, 100 µm; magnification, ×10.](ol-15-03-3685-g03){#f4-ol-0-0-7741}

![Metastasis from rhabdomyosarcoma to the breast. (A) Typical spindle tumor cells with ill-defined margins and (B) skeletal muscle-like tumor cells characterized by eosinophilic cytoplasm in H&E staining at magnification, ×20. (C) Immunohistochemical staining indicated myogenin expression. Scale bar, 100 µm; magnification, ×10.](ol-15-03-3685-g04){#f5-ol-0-0-7741}

![Kaplan Meier analysis of overall survival for patients with metastasis to the breast.](ol-15-03-3685-g05){#f6-ol-0-0-7741}

![Kaplan Meier analysis of overall survival for patients with metastasis to the breast stratified by surgical and non-surgical intervention.](ol-15-03-3685-g06){#f7-ol-0-0-7741}

![Kaplan Meier analysis of overall survival for patients with metastasis to the breast stratified by breast conserving surgery, modified radical mastectomy and non-surgical intervention.](ol-15-03-3685-g07){#f8-ol-0-0-7741}

###### 

Demographic characteristics of patients with metastases to the breast (n=22).

  Characteristics                                     Patients, n (%)
  --------------------------------------------------- -------------------------------------------------------
  Sex                                                 
    Male                                              2 (9.1)
    Female                                            20 (90.9)
  Age, years                                          
    Mean                                              40.5
    Median                                            43
    Range                                             10--62
  History of primary tumor                            
    Known                                             19 (86.4)
    Unknown                                           3 (13.6)^[a](#tfn1-ol-0-0-7741){ref-type="table-fn"}^
  Interval from primary tumor to breast metastasis    
    Mean, months                                      16.5
    Range, months                                     6--56
  Other metastases                                    
    Breast only                                       6 (27.3)
    Other metastases prior to breast                  9 (40.9)
    Simultaneous other metastases                     2 (9.1)
    Other metastases following breast                 5 (22.7)
  Tumor status at presentation of breast metastasis   
    Metastatic disease                                7 (31.8)
    No evidence of disease                            11 (50.0)
    History of other metastases, no NED at present    1 (4.5)
  Intact primary disease                              3 (13.6)^[a](#tfn1-ol-0-0-7741){ref-type="table-fn"}^

One patient was initially diagnosed with a double primary tumor (lung cancer and breast cancer), the breast lesion was pathologically diagnosed postoperatively (modified radical mastectomy) as a metastasis from the lung.

###### 

Clinical characteristics of patients with metastases to the breast.

  Characteristics                                                                Patients, n (%)
  ------------------------------------------------------------------------------ -----------------
  Initial detections                                                             
    Self.checking                                                                14 (63.6)
    Ultrasonography                                                              2 (9.1)
    Mammogram                                                                    2 (9.1)
    CT (including PET.CT)                                                        3 (13.6)
    Unknown                                                                      1 (4.5)
  Clinical symptoms                                                              
    A palpable painless solitary mass                                            14 (63.6)
    Multiple nodules                                                             8 (36.4)
    Skin and nipple changes                                                      1 (4.5)
  Tenderness^[a](#tfn2-ol-0-0-7741){ref-type="table-fn"}^                        2 (9.1)
    Enlarged axillary lymph nodes^[b](#tfn3-ol-0-0-7741){ref-type="table-fn"}^   10 (45.5)
  Tumor size, cm                                                                 
    Mean                                                                         2.9
    Range                                                                        0.8.12
  Breast involvement                                                             
    Unilateral, left                                                             10 (45.5)
    Unilateral, right                                                            8 (36.4)
    Bilateral                                                                    4 (18.2)
    Quadrant                                                                     
    Inner^[c](#tfn4-ol-0-0-7741){ref-type="table-fn"}^: Upper/mid/lower          8 (30.8)
    Outer^[d](#tfn5-ol-0-0-7741){ref-type="table-fn"}^: Upper/mid/lower          18 (69.2)

No evidence of inflammatory skin changes.

Simultaneous enlarged supraclavicular lymph nodes in 4 cases.

Upper/middle/lower, 4/3/1, respectively.

Upper/middle/lower, 15/2/1, respectively. CT, computerized tomography; PET.CT, positron emission tomography. computerized tomography.

###### 

Ultrasonic and mammographic findings of breast metastases^[a](#tfn6-ol-0-0-7741){ref-type="table-fn"}^.

  Characteristics                            Patients, n
  ------------------------------------------ ------------------------------------------------
  Ultrasonic findings (n=14)                 
    Circumscribed/speculated margins         8/6
  Posterior echo                             
  No change/attenuation/enhancement          8/3/3
    BI-RADS category, II/III/IVa/IVb/IVc/V   1/1/1/2/2/7
    Calcifications                           2
    Cooper\'s ligaments involved             1
    Skin/subcutaneous nodule                 3
    Vascularity                              8^[b](#tfn7-ol-0-0-7741){ref-type="table-fn"}^
  Mammographic findings (n=5)                
  Margins, circumscribed/speculated          3/2
    BI-RADS category, I/IVb/V                1/3/1
    Calcifications                           2

Ultrasonic or mammographic imaging records were available in 18 cases; one only had a PET-CT scan, 3 patients unknown

Abnormal blood flow signals detected by Doppler imaging either inside (7 cases) or surrounding (1 case) the lesion. BI-RADS, breast imaging-reporting and data system; PET-CT, positron emission tomography-computerized tomography.

###### 

Histological features in different types of carcinoma in patients with breast metastases.

  Primary site   Pathological pattern                                                                Sex   Age, year   Specific histological features            Nipple/skin invasion^[a](#tfn8-ol-0-0-7741){ref-type="table-fn"}^   Lymphovascular emboli   Axillary LN metastases^[a](#tfn8-ol-0-0-7741){ref-type="table-fn"}^   Calcification   Necrosis                      Other invasion                IHC^[b](#tfn9-ol-0-0-7741){ref-type="table-fn"}^
  -------------- ----------------------------------------------------------------------------------- ----- ----------- ----------------------------------------- ------------------------------------------------------------------- ----------------------- --------------------------------------------------------------------- --------------- ----------------------------- ----------------------------- --------------------------------------------------
  Lung           Adenocarcinoma                                                                      F     44          No                                        \+ (nipple)                                                         \+                      \+                                                                    −               \+                            \+ (pectoralis major; ribs)   \+
  Lung           Adenocarcinoma                                                                      F     60          No                                        \+ (nipple, skin)                                                   \+                      \+                                                                    \+              −                             \+ (extra nodal)              \+
  Lung           Adenocarcinoma^[c](#tfn10-ol-0-0-7741){ref-type="table-fn"}^                        F     45          No, spindle cells                         NA                                                                  −                       NA                                                                    −               −                             −                             \+
  Lung           Adenocarcinoma                                                                      F     62          No                                        NA                                                                  −                       NA                                                                    \+              −                             −                             \+
  Lung           Adenocarcinoma                                                                      F     44          No                                        NA                                                                  −                       NA                                                                    −               −                             −                             \+
  Nasopharynx    Undifferentiated carcinoma                                                          F     41          No                                        NA                                                                  −                       NA                                                                    −               −                             −                             \+
  Nasopharynx    Undifferentiated carcinoma                                                          F     24          No                                        NA                                                                  −                       NA                                                                    −               −                             −                             \+
  Nasopharynx    Undifferentiated carcinoma                                                          M     46          Yes, cells with vesicular nuclei          NA                                                                  −                       NA                                                                    −               −                             −                             −
  Nasopharynx    Undifferentiated carcinoma                                                          M     45          Yes, cells with vesicular nuclei          −                                                                   −                       \+                                                                    −               −                             −                             \+
  Ovary          Serous papillary adenocarcinoma                                                     F     50          Yes, micropapillary                       −                                                                   −                       \+                                                                    \+              −                             −                             \+
  Ovary          Serous papillary adenocarcinoma                                                     F     42          Yes, papillary                            NA                                                                  \+                      NA                                                                    −               \+                            \+ (pectoralis major)         \+
  Ovary          Serous papillary adenocarcinoma                                                     F     39          Yes, papillary                            NA                                                                  −                       NA                                                                    −               −                             −                             −
  Duodenum       Adenocarcinoma                                                                      F     29          Yes, intracytoplasmic mucinous vacuoles   NA                                                                  −                       NA                                                                    −               \+                            −                             −
  Stomach        Adenocarcinoma                                                                      F     41          No, rare signet-ring cell                 NA                                                                  −                       NA                                                                    −               −                             −                             \+
  Thyroid        Papillary thyroid carcinoma                                                         F     34          Yes, papillary and typical colloid        NA                                                                  \+                      NA                                                                    −               \+ (sternoclavicular joint)   \+                            −
  Cervix         Small cell neuroendocrine carcinoma^[d](#tfn11-ol-0-0-7741){ref-type="table-fn"}^   F     37          Yes, small cells                          NA                                                                  −                       NA                                                                    −               −                             −                             −

Nipple/skin invasion and axillary lymph nodes metastases were evaluated in patients who underwent modified radical mastectomy.

Positive for patients who had immunohistochemistry staining.

Pathological diagnosis of lesion in lung was adenosquamous carcinoma.

Pathological diagnosis of lesion in cervix was combined adenocarcinoma and small cell neuroendocrine carcinoma. F, female; M, male; LN, lymph node; IHC, immunohistochemistry; NA, data not available.

###### 

Histological features in different types of non-carcinoma in patients with breast metastases.

  Primary site       Pathological pattern           Sex   Age, years   Specific histological features                                      Nipple (or skin) invasion^[a](#tfn13-ol-0-0-7741){ref-type="table-fn"}^   Lymphovascular emboli   Axillary LN metastases^[a](#tfn13-ol-0-0-7741){ref-type="table-fn"}^   Calcification   Necrosis   Other invasion   IHC^[b](#tfn14-ol-0-0-7741){ref-type="table-fn"}^
  ------------------ ------------------------------ ----- ------------ ------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------- ---------------------------------------------------------------------- --------------- ---------- ---------------- ---------------------------------------------------
  Skin (abdominal)   Melanoma                       F     49           No                                                                  −                                                                         −                       \+                                                                     −               −          −                \+
  Skin (foot)        Melanoma                       F     46           Yes, pigment                                                        NA                                                                        −                       NA                                                                     −               \+         −                \+
  Eyes               Melanoma                       F     45           Yes, pigment and intranuclear inclusions                            NA                                                                        −                       NA                                                                     −               \+         −                −
  Palm               Rhabdomyosarcoma (embryonic)   F     20           Yes, spindle cells, eosinophilic cytoplasm                          \+ (nipple, skin)                                                         −                       \+                                                                     −               −          −                −
  Nasal cavity       Rhabdomyosarcoma (alveolar)    F     41           No                                                                  −                                                                         −                       −                                                                      −               −          −                \+
  Abdomen            Wilms\' tumor                  F     10           Yes, epithelial-like cells and undifferentiated mesenchymal cells   NA                                                                        −                       NA                                                                     −               \+         −                \+

Data not available.

Nipple/skin invasion and axillary lymph nodes metastases were evaluated in patients who underwent modified radical mastectomy.

Positive for patients who had immunohistochemistry staining. F, female; M, male; LN, lymph node; IHC, immunohistochemistry; NA, data not available.
